Description
What Is GLP 3 (Reta)?
GLP 3 (Reta), also identified by the development code LY3437943, is a synthetic lipidated peptide designed as a triple agonist of the GIP, GLP-1 and glucagon receptors.
The compound is studied in laboratory settings to examine multi-receptor incretin signaling, receptor activation and related metabolic pathways. Its 39-amino-acid structure includes a fatty-acid modification intended to support albumin binding and extended experimental activity.
GLP 3 (Reta) remains an investigational research compound and is not an approved medicine. It is supplied exclusively for legitimate in-vitro laboratory and analytical research.
Research Context
GLP 3 (Reta) may be used in controlled research examining:
- GIP, GLP-1 and glucagon receptor binding
- Receptor-mediated cAMP signaling
- Incretin signaling in laboratory cell models
- Comparative single-, dual- and triple-receptor agonist research
- Metabolic-flux and energy-expenditure studies in research models
- Albumin-binding and experimental stability characterization
- Structure–activity relationships of engineered incretin peptides
This information describes research context only and must not be presented as medical, treatment or human-use guidance.
Reviews
There are no reviews yet.